New York’s Codagenix and Brussels-based biomanufacturing platform company Univercells will collaborate on an undisclosed, “high-priority human vaccine target with global public health demand,” the companies announced last week.

Univercells will assess the live attenuated candidate from Codagenix with an eye toward eventual commercial production on its proprietary manufacturing platform, according to the joint press release.

Adjuvant Capital backs both companies. The Codagenix…

The state of the hunt:

Moderna’s became the second Covid-19 vaccine to receive U.S. FDA Emergency Use Authorization.
  COVAX has secured nearly 2 billion doses of vaccines but faces a “very high” failure risk, according to Reuters.
  Canada, Saudi Arabia and the United States have begun immunization campaigns using Pfizer/BioNTech’s jab.



Approved or authorized vaccines
The U.S. FDA granted Emergency Use Authorization (EUA…

Institute of India (SII) has spun off its Covid-19 vaccine portfolio into a new company, per local media.

According to its website, Serum Institute Life Sciences will “leverage Serum Institute’s current manufacturing capabilities” and has begun construction of a new, billion-dose-capacity GMP facility. The company currently has five Covid-19 vaccines in its pipeline, including two developed in-house and three more from partnerships with AstraZeneca, Codagenix and Novavax.


The state of the hunt:

Vaccine candidates from Novavax and J&J’s Janssen subsidiary entered Phase 3.
  Chinese regulators are reviewing inactivated vaccine candidates from CNBG for conditional authorization.
  Fujifilm’s flu drug Avigan (favipiravir) met its primary endpoint in a Phase 3 trial for treatment of Covid-19.



Phase 3 candidates:
China weighs approval of CNBG shots: State regulators are reviewing CNBG’s two…

The state of the hunt:

China’s Sinovac and CNBG separately touted preliminary Phase 1/2 results for inactivated vaccine candidates—with favorable safety and immunogenicity profiles for both.
  Teams in China, Germany, Japan, South Korea, Russia and the United Kingdom are set to begin first-in-human clinical trials for six different investigational vaccines.
  Commonly available steroid dexamethasone reduced mortality in Covid-19 patients requiring respiratory support, an…

More companies worldwide announced vaccine and treatment development efforts in the third week since WHO declared Covid-19 a Public Health Emergency of International Concern.

Sanofi joined the ranks of multinationals pursuing a vaccine with its announcement yesterday of a partnership with the U.S. Biomedical Advanced Research and Development Authority to develop a novel coronavirus shot built on a baculovirus-based recombinant DNA platform.

Meanwhile, several developing country…

New York-based synthetic biology company Codagenix announced this week that it has added $20 million in Series B financing to its current $18 million in funding to support development of its live attenuated respiratory syncytial virus (RSV) vaccine, as well as a broadly-protective influenza shot and an oncolytic virus therapy for triple-negative breast cancer.

The financing will also enable the Stony Brook University spinoff to launch “two new vaccine development programs targeting…